ATRA + ATO + Idarubicin (APL high-risk) — modified APL0406 / AIDA-style

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ATRA` `DRUG-ATO` `DRUG-IDARUBICIN`

ID	`REG-ATRA-ATO-IDA-APL`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-APL0406-LOCOCO-2013` `SRC-ELN-APL-2019` `SRC-NCCN-AML-2025`

Notes

1L for high-risk APL (Sanz WBC >10) per ELN 2019. ATRA + ATO + idarubicin is preferred when ATO available; classic AIDA (ATRA + idarubicin alone) is acceptable alternative without ATO. Hyperleukocytosis-related DS prophylaxis and DIC management are mandatory. Cumulative anthracycline dose tracking. Pregnancy gating mandatory (all 3 agents teratogenic). STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-APL-1L-ATRA-ATO-IDA - IND-APL-1L-ATRA-ATO-IDA